Maxzimaa Pharmaceuticals Private Limited, a active private limited company, was established on 30 December 2014 in Azadpur, Delhi, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U24100DL2014PTC274793. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹2.50 M.
It upholds a compliant status. Employing 57 professional, Its leadership includes Sucheta Dhawan (Director), Dhiraj Joshi (Director), Lovpreet Moti (Director). Past directors included Shweta Pathak, Rachana Khatri, Prabhu Jyot Singh. It holds ₹4.50 M open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 403, Amber Tower, 4Th Floor, Azadpur Commercial Complex,, Azadpur, Delhi, 110033.
U24100DL2014PTC274793
274793
30 December 2014
₹5.00 M
₹2.50 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Maxzimaa Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sucheta Dhawan | Director | 20 Jan 2015 | Current |
| Dhiraj Joshi | Director | 20 Jan 2015 | Current |
| Lovpreet Moti | Director | 20 Jan 2015 | Current |
| Rachana Khatri | Director | 18 Oct 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 20 Jan 2015 | Past |
| Pramod Abcsdd | Additional Director | 19 Nov 2018 | Past |
| Pramod Abcsdd | Director | 20 Jan 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Maxzimaa Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.08% increase. The company also saw a substantial improvement in profitability, with a 2425.57% increase in profit. The company's net worth moved up by a moderate rise of 1.65%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Maxzimaa Pharmaceuticals had a public holding of 96.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹4,500,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2025 | Others | ₹4.50 M | Open |
Explore comprehensive loan charge details -
Maxzimaa Pharmaceuticals has a workforce of 57 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Maxzimaa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxzimaa Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Others amounted to Rs. 4.50 M with Charge ID 101095026 was registered on 28 Mar 2025. was recorded as a recent event.
Maxzimaa Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Maxzimaa Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
Progress on Rachana Khatri was appointed as a Director was appointed as a Director on 18 Oct 2018 & has been associated with this company since 7 years 1 month . was documented.
Progress on Sucheta Dhawan was appointed as a Director was appointed as a Director on 20 Jan 2015 & has been associated with this company since 10 years 10 months . was documented.
The activity Dhiraj Joshi was appointed as a Director was appointed as a Director on 20 Jan 2015 & has been associated with this company since 10 years 10 months . was completed.
The CIN of Maxzimaa Pharmaceuticals Private Limited is U24100DL2014PTC274793.
Maxzimaa Pharmaceuticals Private Limited is headquartered at 403, Amber Tower, 4Th Floor, Azadpur Commercial Complex,, Azadpur, Delhi, 110033.
Maxzimaa Pharmaceuticals Private Limited was incorporated on 30 December 2014.
The current directors of Maxzimaa Pharmaceuticals Private Limited are
The primary industry of Maxzimaa Pharmaceuticals Private Limited is Trade.
Maxzimaa Pharmaceuticals Private Limited is unlisted.
The authorized capital of Maxzimaa Pharmaceuticals Private Limited is ₹5.00 M, and the paid-up capital is ₹2.50 M.
The compliance status of Maxzimaa Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX